抗 BCMA CAR-T 细胞治疗后难治性血液学毒性的干细胞支持门诊挽救：病例报告

英文原题：Outpatient Rescue With Stem Cells Boost for Refractory Hematotoxicity Following anti-BCMA CAR T-Cell Therapy: A Case Report.

查看英文原题

Outpatient Rescue With Stem Cells Boost for Refractory Hematotoxicity Following anti-BCMA CAR T-Cell Therapy: A Case Report.

PubMed 2026/06/04（内容时间） Case Rep Hematol Q4 · IF 0.7（JCR 2025）

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

靶点：BCMA 技术：CAR-T 地区：其他地区：欧洲

登录后收藏与关注全文解读加入对比

中文摘要

抗BCMA CAR-T 细胞治疗后出现持久且难治性血液学毒性，是一种可导致显著发病负担的严重并发症。当输血和造血生长因子等常规支持措施无效时，亟需其他治疗策略。本研究报告一名55岁男性接受伊德卡布他基因维克仑赛治疗后出现持续性血细胞减少。未进行预处理化疗，输注冷冻保存的自体干细胞（干细胞加强输注）后，患者在14天内迅速且完全恢复造血功能。本病例提示，干细胞加强输注可能是挽救CAR-T 治疗后持久性血液学毒性的策略，并强调需要开展前瞻性多中心研究，以规范该干预的适应证、时机和操作流程。

展开英文摘要原文

Prolonged and refractory hematotoxicity is a severe complication of anti-BCMA CAR-T cell therapy, associated with substantial morbidity. When conventional supportive measures (transfusions and hematopoietic growth factors) fail, alternative strategies are urgently needed.

We report the case of a 55-year-old man who developed persistent cytopenias after idecabtagene vicleucel. Reinfusion of cryopreserved autologous stem cells (stem cell boost), administered without conditioning chemotherapy, resulted in rapid and complete hematopoietic recovery after 14 days. This case highlights the potential of stem cell boost as a salvage approach for prolonged post-CAR-T hematotoxicity and underscores the need for prospective multicenter studies to standardize indications, timing, and procedures for this intervention.

论文信息

作者: Loukhnati M、Hebraud B、Cazaux M、Borel C、Bories P、Martignoles JA、Granell M、Cougoul P
第一作者单位: Faculty of Medicine and Pharmacy, Department of Hematology, Mohammed VI University Hospital, Cadi Ayyad University, Marrakesh, Morocco, uca.ma.
通讯作者单位: Department of Hematology, Toulouse University Cancer Institute - Oncopole, University of Toulouse, Toulouse, France.France
期刊: Case reports in hematology2026

原文标识: PubMed 42257064　·　DOI 10.1155/crh/1558475

在 PubMed 查看 → 出版商原文（DOI）报告译文或资料问题 →